Ketamine, a fast-acting antidepressant, is a racemic mixture, composed of equal amounts of R- and S-ketamine. Preclinical studies are comparing them to better understand their role in therapeutic and undesirable effects. An important research gap is that studies do not use long clinically relevant protocols to compare the desired and undesired effects of ketamine enantiomers in modeled and...
Schizophrenia (SCZ) has limited treatment options, often with significant side effects. Cannabidiol (CBD), a non-euphoric phytocannabinoid, has shown potential as a novel therapeutic option in SCZ due to antipsychotic-like, anti-inflammatory, and antioxidant properties. We compared the therapeutic effects of CBD and risperidone (RISP) in a rat model of SCZ induced by sub-chronic ketamine (KET),...
The effective treatment of major depressive disorder remains one of the biggest public health challenges globally. For moderate to severe cases, pharmacotherapy often falls short, leading to treatment-resistant depression. Electroconvulsive therapy (ECT) has generally been considered the gold standard for severe cases of treatment-resistant depression. However, emerging evidence suggests that...
Borderline personality disorder (BPD) is a mental health condition characterized by a pervasive pattern of impulsivity, affective dysregulation, and cognitive-perceptual symptoms. Treatment of BPD remains a significant challenge to mental health clinicians. People who suffer from BPD frequently have comorbid psychiatric disorders, which makes treatment more complex. This case study describes a...
Depression is a common yet potentially debilitating mood disorder with complex neurobiological underpinnings, including deficiencies in monoaminergic and glutamatergic signaling, overactivity of the lateral habenula, and dysregulation of brain-derived neurotrophic factor (BDNF) signaling. Ketamine has emerged as a mechanistically novel, effective, and rapidly acting antidepressant. Ketamine's...
Ketamine, in doses suitable to induce anaesthesia in humans, gives rise to a unique state of unresponsiveness accompanied by vivid experiences and sensations, making it possible to disentangle the correlated but distinct concepts of conscious awareness and behavioural responsiveness. This distinction is often overlooked in the study of consciousness. The mathematical framework of connectome...
Behavioural Brain ResearchMarch 28, 2025Teresa Belem Mares-Barbosa, Ares Orlando Cuellar-Santoyo, Victor Manuel Ruiz-Rodríguez et al.3 citations
Ketamine hydrochloride serves multiple purposes, including its use as a general anesthetic, treatment for depression, and recreational drug. In studies involving rodents, ketamine is utilized as a model for schizophrenia. However, it is unclear whether age affects the behavioral response induced by repeated ketamine administration and if it modifies the expression levels of N-methyl-D-aspartate...
The prevalence of stress-induced disorders, including depression, anxiety, posttraumatic stress disorder, and postpartum depression, has been increasing, while current treatment approaches are limited. As a result, researchers are exploring alternative treatments that include ketamine as a prophylactic against these disorders. This review provides an overview of the current knowledge on the use...
Ketamine has demonstrated early promise for treating substance use disorder (SUD). Despite the emerging evidence for ketamine-based approaches for SUD, little has been published on the integration of ketamine-assisted psychotherapy (KAP) with existing pharmacologic, psychosocial, and peer-support approaches to treatment and recovery, including 12-step programs. Here, we present the case of a...
Low-dose ketamine is an N-methyl-D-aspartate receptor antagonist that exerts an antidepressant effect on patients with treatment-resistant depression (TRD). This antidepressant effect may extend beyond the glutamatergic hypothesis. Nevertheless, the roles of genes encoding other monoamine neurotransmitters (i.e., serotonin and dopamine) in the neuromechanism of low-dose ketamine remain unknown....